COVID 19 Cough chamber shows six feet not far enough Neuroscience News

Summary: Droplets from a cough travel at a speed of 1.2 meters per second at peak velocity. Findings reveal that there is no logical reason to suggest 6 foot of physical distance is substantial at reducing coronavirus transmission.

Source: Western University

A recent Western-led study says two meters might not be far enough away if someone lets an uncovered cough loose in your direction – meaning sneeze and cough etiquette is more than a simple social nicety, but a key to stopping the spread of diseases like COVID-19.

Image: Western Engineering’s cough chamber is a two-metre enclosed cube with an opening and chin rest in the front, which is used as an access point for study participants to cough. Within the cube, a camera and a laser are used to determine the velocity of the expelled droplets from the cough. The image is credited to Frank Neufeld.

NewImage

TENANT AMENITIES

  • Proximate to Rockville Metro Station and Rockville Town Square, which offers major amenities, including restaurants, retail, lodging, and banking 
  • Access to Route 28, Route 355, I-270, and Route 200/ICC 
  • Ample parking 
  • Direct loading 
  • Separate metering for utilities 
  • Emergency generator 
  • Zoned for Mixed-Use Business (MXB)

Click here for more information.

NewImage

Johns Hopkins University, whose global count of COVID-19 cases and deaths has become one of the most popular sources for information about the disease, has unveiled a new United States map that dives into the pandemic on a county level.

The U.S. map provides information about counties’ health infrastructure, population and policies and cases related to COVID-19, the disease caused by the coronavirus.

Image: Johns Hopkins University’s map tracking the COVID-19 has added county data, including snapshot infographics, like this one of Prince George’s County, for every county in the country. (Johns Hopkins University)

NewImage

Sanofi and GSK, two of the biggest names in vaccine development, are joining forces on creating a coronavirus vaccine, the companies announced Tuesday.

Sanofi launched the project in February; what’s new is GSK’s contribution of an adjuvant — a substance that is added to a vaccine to enhance people’s immune responses.

Image: JOSEPH N. DISTEFANO

Novel Coronavirus SARS CoV 2 Coronavirus disease 2019 Wikipedia

Current COVID-19 tests detect the presence of the SARS-CoV-2 viral RNA genome in patients’ samples through RT-PCR. They are designed to identify who has the virus in their system, at the time of testing. But, testing in the United States has been inadequate on multiple levels. There are not enough tests, leaving some patients waiting in long lines outside of the hospital and others sleeping overnight in their cars, waiting to be tested. Also, the tests’ levels of sensitivity (identifying those with the disease correctly) and specificity (identifying those without the disease) have been called into question.

 

Bayh Dole 40 Event

The world is anxiously awaiting effective treatments for Covid-19, which is ravaging most countries. Fortunately, some of the best minds in our public and private sectors are putting everything they have into developing effective vaccines, drugs, and tests that are so desperately needed. Because of the Bayh-Dole Act, which allows academic institutions and federal laboratories to effectively license their discoveries so they can make the leap from being laboratory concepts into useful products, these partnerships are proceeding at full speed. Unfortunately, some want to undo this model at the very time we need it the most.

 

money

On Thursday morning, the Board of Governors of the Federal Reserve System (Board) released the highly anticipated details of its massive $600 billion Main Street Lending program (Program) to support small and mid-sized businesses with up to 10,000 employees. The Program is particularly welcomed by businesses that are too large to be eligible for loans under for the Paycheck Protection Program (PPP).

 

AstraZeneca Logo

British drug giant AstraZeneca is rushing forward a big clinical trial for its blood cancer drug Calquence because it has shown early promising results in later-stage COVID-19 patients—those in intensive care units and on ventilators. Calquence and top-selling leukemia drug Imbruvica are the latest hopes in getting coronavirus patients off ventilators, where there is a 50% mortality rate.  

 

NewImage

The COVID-19 crisis brought a shortage of ventilators that can help people battling the lung condition caused by the disease and led to a dire puzzle that leaders in the government and healthcare system are working to solve: how to acquire enough ventilators so that doctors don’t have to face the choice of refusing the machine to someone who needs it.

Image: The ventilator splitter prototype. (Photo courtesy of Johns Hopkins/Will Kirk)

This illustration, created at the Centers for Disease Control and Prevention (CDC), reveals ultrastructural morphology exhibited by coronaviruses. A novel coronavirus, named Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China in 2019. The illness caused by this virus has been named coronavirus disease 2019 (COVID-19). (CDC/Alissa Eckert, MS)

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader menu of therapeutic options.

 

PitchBook Logo

SEATTLE, April 14, 2020 /PRNewswire/ -- After elevated venture capital (VC) investment in the past few years, deal activity maintained momentum in the first quarter of 2020 amid the impending economic downturn due to the COVID-19 pandemic, which will slow activity through the rest of the year, according to the PitchBook-NVCA Venture Monitor, the authoritative quarterly report on venture capital activity in the entrepreneurial ecosystem jointly produced by PitchBook and the National Venture Capital Association (NVCA), with support from Silicon Valley Bank and Carta.

 

2020 BioHealth Capital Region Forum Planning Committee Update

We hope you and your families are well. This is a reminder that due to COVID19 the BioHealth Capital Region Forum, originally scheduled to take place this week, April 14th and 15th at AstraZeneca, has been postponed. 

We are looking into combining the BioHealth Capital Region Forum with the BioHealth Capital Region Investment Conference which tentatively will be held between October 19th and 21st, 2020. We will advise you of our future direction on these events as soon as we develop our path forward. Please save these dates until we finalize the details as we hope to have an in-person event at that time. Thank you for your patience and understanding during these challenging times.

- BioHealth Capital Region Forum Planning Committee

NewImage

Rockville, Md. — In a greater effort to ensure that the Maryland National Capital Region can emerge as quickly as possible from the expected economic hardships of the COVID-19 coronavirus, the Montgomery County Economic Development Corporation (MCEDC) announced today that it has joined with its state peers in the Greater Washington metropolitan area to form a regional alliance to support an economic recovery. 

A Joint Statement of collaboration formalizing the Maryland National Capital Region Economic Development Alliance (MNCREDA) was signed virtually by the leaders of the economic development organizations representing six counties. The Joint Statement document and a photo of its virtual signing are attached. 

Image: https://thinkmoco.com

Aphena Pharma Solutions Logo

BALTIMORE, MD (April 13, 2020) – Aphena Pharma Solutions, an industry leading organization that provides packaging and manufacturing solutions for the medical industry, is planning to expand its pharmaceutical manufacturing operations in the Town of Easton. The company, which currently operates within a 110,000 square foot facility at 7978 Industrial Park Road, is purchasing an additional 54,000 square foot facility adjacent to its existing location. Building renovations and the installation of new equipment is expected to begin this year, with an estimated completion time of December 2020. Aphena currently employs 150 full-time workers and plans to add an additional 100 jobs in Talbot County over the next two years.

 

Homepage emocha Mobile Health Inc

In response to the COVID-19 crisis, emocha Mobile Health has implemented a remote monitoring service powered by human engagement to support health systems including Johns Hopkins Medicine and LifeBridge Health-affiliated hospitals. emocha uses short, asynchronous video check-ins to identify, track, and manage symptoms of healthcare professionals who have been exposed to COVID-19.

Healthcare workers are on the front lines of the COVID-19 (coronavirus) pandemic, and ensuring their safety and availability is critical. The virus is spreading rapidly across the globe with more than 35,350 confirmed cases in the United States as of March 23. As a result, this highly infectious and novel disease requires strategies to protect the public’s health and to slow the rate of transmission.